Samsung Biologics Receives Lowest-Risk ESG Rating
Samsung Biologics received the lowest-risk rating in Morningstar Sustainalytics’ ESG assessment on Nov. 3, 2026.
Samsung Biologics received the lowest-risk rating in Morningstar Sustainalytics’ ESG assessment on Nov. 3, 2026.